cis-Dichlorodiammineplatinum(II) in non-small cell carcinoma of the lung

Richard J. Gralla, E. Cvitkovic, R. B. Golbey

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The role of cis-dichlorodiammineplatinum (II) (cis-platinum) as a single agent in non-small cell lung cancer has not been clearly defined, and extensive phase II studies have not been conducted. However, objective responses were noted in several early clinical trials. A review of these reports, including combinations with conventional agents, shows 15 partial responses among 100 patients. Results are presented on a new protocol using high-dose cis-platinum with mannitol-induced diuresis combined with cyclophosphamide and Adriamycin. An overall partial response rate of 28% was observed, including a 38% response rate in good performance status patients, with a median survival of 16 months in responding patients. Data from recent combination protocols do not define the activity of cis-platinum as a single agent, but suggest that it may be useful in non-small cell carcinoma of the lung.

Original languageEnglish (US)
Pages (from-to)1585-1588
Number of pages4
JournalCancer Treatment Reports
Volume63
Issue number9-10
StatePublished - 1979
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Cisplatin
Diuresis
Mannitol
Doxorubicin
Cyclophosphamide
Clinical Trials
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gralla, R. J., Cvitkovic, E., & Golbey, R. B. (1979). cis-Dichlorodiammineplatinum(II) in non-small cell carcinoma of the lung. Cancer Treatment Reports, 63(9-10), 1585-1588.

cis-Dichlorodiammineplatinum(II) in non-small cell carcinoma of the lung. / Gralla, Richard J.; Cvitkovic, E.; Golbey, R. B.

In: Cancer Treatment Reports, Vol. 63, No. 9-10, 1979, p. 1585-1588.

Research output: Contribution to journalArticle

Gralla, RJ, Cvitkovic, E & Golbey, RB 1979, 'cis-Dichlorodiammineplatinum(II) in non-small cell carcinoma of the lung', Cancer Treatment Reports, vol. 63, no. 9-10, pp. 1585-1588.
Gralla, Richard J. ; Cvitkovic, E. ; Golbey, R. B. / cis-Dichlorodiammineplatinum(II) in non-small cell carcinoma of the lung. In: Cancer Treatment Reports. 1979 ; Vol. 63, No. 9-10. pp. 1585-1588.
@article{e1be1dfdb9a44ec49fcdbebf0dfa8563,
title = "cis-Dichlorodiammineplatinum(II) in non-small cell carcinoma of the lung",
abstract = "The role of cis-dichlorodiammineplatinum (II) (cis-platinum) as a single agent in non-small cell lung cancer has not been clearly defined, and extensive phase II studies have not been conducted. However, objective responses were noted in several early clinical trials. A review of these reports, including combinations with conventional agents, shows 15 partial responses among 100 patients. Results are presented on a new protocol using high-dose cis-platinum with mannitol-induced diuresis combined with cyclophosphamide and Adriamycin. An overall partial response rate of 28{\%} was observed, including a 38{\%} response rate in good performance status patients, with a median survival of 16 months in responding patients. Data from recent combination protocols do not define the activity of cis-platinum as a single agent, but suggest that it may be useful in non-small cell carcinoma of the lung.",
author = "Gralla, {Richard J.} and E. Cvitkovic and Golbey, {R. B.}",
year = "1979",
language = "English (US)",
volume = "63",
pages = "1585--1588",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "9-10",

}

TY - JOUR

T1 - cis-Dichlorodiammineplatinum(II) in non-small cell carcinoma of the lung

AU - Gralla, Richard J.

AU - Cvitkovic, E.

AU - Golbey, R. B.

PY - 1979

Y1 - 1979

N2 - The role of cis-dichlorodiammineplatinum (II) (cis-platinum) as a single agent in non-small cell lung cancer has not been clearly defined, and extensive phase II studies have not been conducted. However, objective responses were noted in several early clinical trials. A review of these reports, including combinations with conventional agents, shows 15 partial responses among 100 patients. Results are presented on a new protocol using high-dose cis-platinum with mannitol-induced diuresis combined with cyclophosphamide and Adriamycin. An overall partial response rate of 28% was observed, including a 38% response rate in good performance status patients, with a median survival of 16 months in responding patients. Data from recent combination protocols do not define the activity of cis-platinum as a single agent, but suggest that it may be useful in non-small cell carcinoma of the lung.

AB - The role of cis-dichlorodiammineplatinum (II) (cis-platinum) as a single agent in non-small cell lung cancer has not been clearly defined, and extensive phase II studies have not been conducted. However, objective responses were noted in several early clinical trials. A review of these reports, including combinations with conventional agents, shows 15 partial responses among 100 patients. Results are presented on a new protocol using high-dose cis-platinum with mannitol-induced diuresis combined with cyclophosphamide and Adriamycin. An overall partial response rate of 28% was observed, including a 38% response rate in good performance status patients, with a median survival of 16 months in responding patients. Data from recent combination protocols do not define the activity of cis-platinum as a single agent, but suggest that it may be useful in non-small cell carcinoma of the lung.

UR - http://www.scopus.com/inward/record.url?scp=0018568985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018568985&partnerID=8YFLogxK

M3 - Article

C2 - 498158

AN - SCOPUS:0018568985

VL - 63

SP - 1585

EP - 1588

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 9-10

ER -